stele
11 Jul 2016
Re: avo ticking up [link]
brightonboyaswell
11 Jul 2016
Re: avo ticking up Director buys I guess
tikky
11 Jul 2016
avo ticking up bought at118 any news why it ticking up ? aware Tom sell articleimho
InsanityBeckons
04 Jul 2016
Re: Consolidation Chck out Tom Winniith's recent articles and you may see why
5haggy
04 Jul 2016
Consolidation Last week's 25:1 consolidation doesn't seem to have done any favours for the share price - it continues in a downward trajectory. Shame!
romanchariot
15 Jun 2016
Tom Winnifrith [link]
asianfriend
01 Jun 2016
Re: Featured on Bearcast Interesting post but I don't know Bearcast and their historical accuracy in forecasting. My view is this company is either very cheap if they manage to put their proton accelerator together on time without mishap, or way overvalued if there are significant production problems. At this stage it appears all is on schedule. Not so worried about share consolidation which in my experience has been positive but perhaps more concerned about the dilutive effects of future fund raisings . Overall I think this share provides an interesting reward/risk balance and to use the old cliché ---better to travel than arrive.
Simbr
01 Jun 2016
AVO progress Took this from Research tree, it's from Beaufort this morn...Advanced Oncotherapy has made a significant progress in the FY2015, keeping its promises and delivered its development milestones to the timeline. In February 2016, AVO announced industrialisation agreement with Thales for LIGHT system, and further strengthened its financing through securing a £24m vendor financing agreement with Metric Capital, a pan- European private capital fund manager, to fully fund the installation of the Group’s first LIGHT machine in Harley Street. This is important news for AVO as it demonstrated not only a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cashflow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. In order to meet its target for the first commercial sales of LIGHT in 2017, AVO’s priorities will be to ensure the components of the LIGHT machine is compliant with the associated regulatory requirements, initial installation into the UK and to pursue commercial roll-out of the technology through existing and new partners. The Group continued to strengthen its team by appointing highly experienced senior management and shuffled the role internally to build a more commercially focussed business. As has been explained in numerous research documents, Beaufort’s commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render ‘first generation’ systems all but obsolete; its development will also has potential to expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity
Simbrad
01 Jun 2016
just pulled this from Beaufort Securities's note out this morning on Research Tree... "Advanced Oncotherapy has made a significant progress in the FY2015, keeping its promises and delivered its development milestones to the timeline. In February 2016, AVO announced industrialisation agreement with Thales for LIGHT system, and further strengthened its financing through securing a £24m vendor financing agreement with Metric Capital, a pan- European private capital fund manager, to fully fund the installation of the Group’s first LIGHT machine in Harley Street. This is important news for AVO as it demonstrated not only a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cashflow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. In order to meet its target for the first commercial sales of LIGHT in 2017, AVO’s priorities will be to ensure the components of the LIGHT machine is compliant with the associated regulatory requirements, initial installation into the UK and to pursue commercial roll-out of the technology through existing and new partners. The Group continued to strengthen its team by appointing highly experienced senior management and shuffled the role internally to build a more commercially focussed business. As has been explained in numerous research documents, Beaufort’s commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render ‘first generation’ systems all but obsolete; its development will also has potential to expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity...."
rollthediceagain
01 Jun 2016
Featured on Bearcast 31st May on share prophets website... not positive, TW describes as a stonking sell given cashburn, conditional funding which probably means AVO needs to raise £30m+ in funding and inflated current market cap. Inclined to agree with that assessment even given potential and progress to date.Given proposed 25:1 consolidation plans (AGM vote) I've decided to bail at a small loss as I think large placing likely and the value of shares held are likely to diminish on consolidation ~ that is what usually happens when non-cash generative companies consolidate.All IMHO of course, I've made the right decision for my own position.
Simbrad
31 May 2016
Stockdale published a note this morning too, it's also on Research Tree.. The key financial highlight in 2015 was raising £20m net through a fund-raising at 8p per share in May. This has enabled Advanced Oncotherapy (AVO) to progress its project to have the first commercial LIGHT system deployed in Harley Street in 2017. Last week’s news of a financing agreement between AVO and Metric Capital ensures the finances are in place to complete this. We shall publish an updated research report with detailed forecasts in due course but ahead of that.
Simbrad
27 May 2016
On Research Tree
Simbrad
27 May 2016
Beaufort published a note this morning, you can access the full note for free... "This is significant and important news for AVO. Not only does it tell us that a senior institutional lender has taken a very close look at the Group and concluded that LIGHT is viable and that its expect its first installation in Harley Street to rapidly become capable of generating strong cash flow, but also that AVO is both sufficiently confident and advanced in its planning to establish a general provision of vendor financing for its prospective international customers. Such proton beam centre financing routes are already routinely used by first generation suppliers to provide the facilities demanded by hospitals and medical practitioners around the globe, so in this respect this is a natural step forward. Moreover, given that AVO is sticking rigidly to its development schedule, whereby the first commercial sales of LIGHT should begin in 2017 whereafter they are expected ramp up in response to significant demand, this facility is likely to become actively used. As has been explained in numerous research documents, Beaufort's commercial scenario for LIGHT is that the cost, safely, operational and size advantages its brings to the world of proton therapy, will effectively render 'first generation' systems all but obsolete; its development will also very significantly expand the international market for such systems from some US$2.5bn annually right now, to a figure potentially ten-times as large as LIGHT becomes the obvious successor to the similarly-priced but now relatively antiquated X-ray radiation systems that have a global installed base in excess of 20,000 units. In this respect, LIGHT uniquely faces a giant and accelerating global opportunity. Beaufort remains a very enthusiastic supporter of Advanced Oncotherapy and repeats..."
penhome
27 May 2016
Updated chart AVO is attempting to break above resistance at 8p and create a new price high for 2016RSI is at its highest so far in 20168/34ema crossoverLooking positive providing it can stay above 8p for 2-3 closes including end of week today.Volume well up again today[link]
Simbrad
26 May 2016
Read Stockdale Securities's note on ADVANCED ONCOTHERAPY PLC (AVO), out this morning on Research Tree. "We view today’s news of a financing agreement between Advanced Oncotherapy (AVO) and Metric Capital positively. The agreement will enable AVO and its partners to complete the London Proton Therapy Centre in Harley Street, the site of the first commercial LIGHT system. We shall publish an updated research report when the 2015 final results are released next month. Ahead of this and on the back of today’s significant progress we are happy to..."
